Back to results
US 12,318,428 B2Granted
VEGFR fusion protein pharmaceutical composition
AssigneeAllgenesis Biotherapeutics Inc.
InventorsTan Nguyen, Pei-Tzu Wu, Yung-Sheng Chang, Madhu Cherukury
Life of this patent
Estimating the term…
Abstract
The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway as well as formulation compositions of such fusion proteins, as well as methods for producing and using the same.
Claims20
A pharmaceutical formulation, the formulation comprising:
- a) a fusion protein in a concentration of about 0.5 mg/mL to about 120 mg/mL, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:
- 17, or SEQ ID NO:
- 18,
- b) trehalose or mannitol at a concentration of about 25 mM to about 250 mM,
- c) a buffering agent selected from a group consisting of sodium phosphate, histidine, sodium citrate, sodium acetate, sodium bicarbonate, and trisodium citrate dihydrate in a concentration of about 10 mM to about 50 mM, and
- d) a surfactant in a concentration of about 0.01 to about 4% w/v, wherein the formulation is at a pH of about 5.5-7.5 and optionally, the formulation further comprises a polysaccharide selected from the group consisting of sodium carboxymethylcellulose, microcrystalline cellulose, or sodium hyaluronate.
3 more elements
A pharmaceutical formulation, the formulation comprising:
- a) a fusion protein comprising the amino acid sequence of SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:
- 17, or SEQ ID NO:
- 18,
- b) trehalose or mannitol at a concentration of about 25 mM to about 250 mM,
- c) a buffering agent selected from a group consisting of sodium phosphate, histidine, sodium citrate, sodium acetate, sodium bicarbonate, and trisodium citrate dihydrate in a concentration of about 10 mM to about 50 mM, and
- d) a surfactant in a concentration of about 0.01 to about 4% w/v, wherein the formulation is at a pH of about 5.5-7.5 and optionally, the formulation further comprises a polysaccharide selected from the group consisting of sodium carboxymethylcellulose, microcrystalline cellulose, or sodium hyaluronate.
3 more elements
Dependencies are inferred from the claim text.